The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...
Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
The active ingredient in Ozempic and Wegovy may help reduce the risk of kidney failure in those with Type 2 diabetes and ...
Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk's weight-loss drug ...
Those with the genetic variants associated with a "hungry gut" lost an average of 14.4% of their body weight after nine months. Given Wegovy's high cost, these genetic markers could be used to ...
The study looked at whether people on Wegovy maintained their weight loss. Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...